Address
2 Executive Campus
Cherry Hill, NJ 08002
United States of America (the)
Phone
201 479 1357
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
April 01, 2021
| Name | Title | Pay | Year Born |
| Andrew LaFrence | President, Chief Executive Officer & Chief Financial Officer | 407,400 | 1963 |
Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.